[Radiosynovectomy with dysprosium-165 iron hydroxide].
Treatment of chronic rheumatoid synovitis (RS) is directed to control the inflammatory process causing pain and disability. Radiation synovectomy is suggested to be an alternative to surgical treatment, but its clinical use has been restricted because of significant leakage (> 10%) associated with the use of the standard radionuclide 90-Yttrium (used as 90-Yttrium silicate colloid) and because of its long physical half-life of 64 hours prolonging the patients' stay in the hospital. 165-Dysprosium possesses promising nuclear properties for the treatment of patients suffering from RS. The maximum soft tissue penetration of its beta-particles is 5.7 mm which is the range being necessary to penetrate the inflamed synovia. Using as carrier ferric hydroxide macroaggregates (DFH) 165-Dy is expected to minimize the cumulative radiation dose to non-target organs by its very low leakage. Animal studies were performed in 13 rats and 6 rabbits to obtain the rationale and safety data for its clinical evaluation. These studies revealed that 98.2 +/- 0.6% of the injected dose remained in the joint with a nontarget organ uptake of less than 0.1%. Clinical results were obtained from 8 patients with rheumatoid arthritis. 24 hours after injection scintigraphy was performed over the treated joint and the liver region revealing no detectable leakage of the injected activity from the joint. Blood pool activity was also assessed revealing a leakage of 0.02% of the dose injected in the knee 24 hours after injection.(ABSTRACT TRUNCATED AT 250 WORDS)
Pirich
C
C
Universitätsklinik für Nuklearmedizin, Wien.
Wanivenhaus
A
A
Graninger
W
W
Kvaternik
H
H
Angelberger
P
P
Pesau
B
B
Havlik
E
E
Flores
J
J
Sinzinger
H
H
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000532:radiotherapy*; D004419:Dysprosium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D005290:Ferric Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D008297:Male; D011817:Rabbits; D011829:Radiation Dosage; D011868:Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051381:Rats; D013583:Synovial Membrane / Q000378:metabolism / Q000528:radiation effects*; D014018:Tissue Distribution
D005290:Ferric Compounds; D011868:Radioisotopes; D004419:Dysprosium; C021024:ferric hydroxide
Radiosynovektomie mit Dysprosium-165-Eisen-Hydroxid.